Shubing Zhang (Hao Jiang)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 16

Top Topics

Sentinel Lymph Node

Neoadjuvant Chemotherapy

Acute Lymphoblastic Leukemia

Cell Proliferation

Top Venues

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Cancer gene therapy

Cell death & disease

Cancer management and research

This page only lists publications with an associated author ORCID identifier.

Publications

Hao Jiang, Yang Wang, Doudou Wen, Rongji Yu, Sayed S Esa, Kefeng Lv, Qing Feng, Jing Liu, Faxiang Li, Lan He, Xiaotang Di, Shubing Zhang
Targeting C21orf58 is a Novel Treatment Strategy of Hepatocellular Carcinoma by Disrupting the Formation of JAK2/C21orf58/STAT3 Complex. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11 (15) (2024)
Shuanghui Liu, Fanggui Shao, Yourong Wang, Yurui Zhang, Hongjia Yu, Ningxin Zhang, Lan He, Qingran Kong, Shubing Zhang, Zhixiong Dong
COX6C expression driven by copy amplification of 8q22.2 regulates cell proliferation via mediation of mitosis by ROS-AMPK signaling in lung adenocarcinoma. Cell death & disease 15 (1) (2024)
Hao Jiang, Yang Wang, Doudou Wen, Rongji Yu, Sayed S Esa, Kefeng Lv, Qing Feng, Jing Liu, Faxiang Li, Lan He, Xiaotang Di, Shubing Zhang
Targeting C21orf58 is a Novel Treatment Strategy of Hepatocellular Carcinoma by Disrupting the Formation of JAK2/C21orf58/STAT3 Complex. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11 (15) (2024)
Hao Jiang, Yang Wang, Doudou Wen, Rongji Yu, Sayed S Esa, Kefeng Lv, Qing Feng, Jing Liu, Faxiang Li, Lan He, Xiaotang Di, Shubing Zhang
Targeting C21orf58 is a Novel Treatment Strategy of Hepatocellular Carcinoma by Disrupting the Formation of JAK2/C21orf58/STAT3 Complex. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11 (15) (2024)
Hao Jiang, Yang Wang, Doudou Wen, Rongji Yu, Sayed S Esa, Kefeng Lv, Qing Feng, Jing Liu, Faxiang Li, Lan He, Xiaotang Di, Shubing Zhang
Targeting C21orf58 is a Novel Treatment Strategy of Hepatocellular Carcinoma by Disrupting the Formation of JAK2/C21orf58/STAT3 Complex. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2024)
Shuanghui Liu, Fanggui Shao, Yourong Wang, Yurui Zhang, Hongjia Yu, Ningxin Zhang, Lan He, Qingran Kong, Shubing Zhang, Zhixiong Dong
COX6C expression driven by copy amplification of 8q22.2 regulates cell proliferation via mediation of mitosis by ROS-AMPK signaling in lung adenocarcinoma. Cell death & disease 15 (1) (2024)
Hao Jiang, Yang Wang, Doudou Wen, Rongji Yu, Sayed S Esa, Kefeng Lv, Qing Feng, Jing Liu, Faxiang Li, Lan He, Xiaotang Di, Shubing Zhang
Targeting C21orf58 is a Novel Treatment Strategy of Hepatocellular Carcinoma by Disrupting the Formation of JAK2/C21orf58/STAT3 Complex. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11 (15) (2024)
Shuanghui Liu, Fanggui Shao, Yourong Wang, Yurui Zhang, Hongjia Yu, Ningxin Zhang, Lan He, Qingran Kong, Shubing Zhang, Zhixiong Dong
COX6C expression driven by copy amplification of 8q22.2 regulates cell proliferation via mediation of mitosis by ROS-AMPK signaling in lung adenocarcinoma. Cell death & disease 15 (1) (2024)
Hao Jiang, Yang Wang, Doudou Wen, Rongji Yu, Sayed S Esa, Kefeng Lv, Qing Feng, Jing Liu, Faxiang Li, Lan He, Xiaotang Di, Shubing Zhang
Targeting C21orf58 is a Novel Treatment Strategy of Hepatocellular Carcinoma by Disrupting the Formation of JAK2/C21orf58/STAT3 Complex. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11 (15) (2024)
Shuanghui Liu, Fanggui Shao, Yourong Wang, Yurui Zhang, Hongjia Yu, Ningxin Zhang, Lan He, Qingran Kong, Shubing Zhang, Zhixiong Dong
COX6C expression driven by copy amplification of 8q22.2 regulates cell proliferation via mediation of mitosis by ROS-AMPK signaling in lung adenocarcinoma. Cell death & disease 15 (1) (2024)
Shubing Zhang, Jinhua Yan, Lan He, Zhiping Jiang, Hao Jiang
STAT5a and SH2B3 novel mutations display malignancy roles in a triple-negative primary myelofibrosis patient. Cancer gene therapy 31 (3) (2023)
Shubing Zhang, Jinhua Yan, Lan He, Zhiping Jiang, Hao Jiang
STAT5a and SH2B3 novel mutations display malignancy roles in a triple-negative primary myelofibrosis patient. Cancer gene therapy 31 (3) (2023)
Shubing Zhang, Jinhua Yan, Lan He, Zhiping Jiang, Hao Jiang
STAT5a and SH2B3 novel mutations display malignancy roles in a triple-negative primary myelofibrosis patient. Cancer gene therapy 31 (3) (2023)
Shubing Zhang, Jinhua Yan, Lan He, Zhiping Jiang, Hao Jiang
STAT5a and SH2B3 novel mutations display malignancy roles in a triple-negative primary myelofibrosis patient. Cancer gene therapy (2023)
Jinhua Yan, Jinzheng Wu, Yang Wang, Xiaotang Di, Hao Jiang, Doudou Wen, Duo Li, Shubing Zhang
A novel RBBP8(p.E281*) germline mutation is a predisposing mutation in familial hereditary cancer syndrome. Journal of molecular medicine (Berlin, Germany) (2023)
Jun Chang, Ling Hong, Yaozhong Liu, Yiwen Pan, Hao Yang, Wenrui Ye, Keli Xu, Zhijian Li, Shubing Zhang
Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer. Cancer management and research 12 (2020)